Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension
Luke J. Laffin, David Rodman, James M. Luther, et al.
JAMA (2023) Vol. 330, Iss. 12, pp. 1140-1140
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

2024 ESC Guidelines for the management of elevated blood pressure and hypertension
John W. McEvoy, Cian P. McCarthy, Rosa María Bruno, et al.
European Heart Journal (2024)
Closed Access | Times Cited: 219
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani, et al.
The Lancet (2023) Vol. 403, Iss. 10424, pp. 379-390
Open Access | Times Cited: 61
The Spectrum of Dysregulated Aldosterone Production: An International Human Physiology Study
Wasita Warachit Parksook, Jenifer M. Brown, Kei Omata, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 9, pp. 2220-2232
Open Access | Times Cited: 13
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3969-3969
Open Access | Times Cited: 13
Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial
Paolo Mulatero, Grégoire Wuerzner, Michael Groessl, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102576-102576
Open Access | Times Cited: 11
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
Stefan R. Bornstein, Dick de Zeeuw, Hiddo J.L. Heerspink, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2128-2138
Open Access | Times Cited: 9
Diagnosis and management of resistant hypertension
Ernesto L. Schiffrin, Naomi D.L. Fisher
BMJ (2024), pp. e079108-e079108
Open Access | Times Cited: 8
Clinical Management of Primary Aldosteronism: An Update
Gian Paolo Rossi, Federico Bernardo Rossi, Chiara Guarnieri, et al.
Hypertension (2024) Vol. 81, Iss. 9, pp. 1845-1856
Closed Access | Times Cited: 7
Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study
Gregory L. Hundemer, Mohsen Agharazii, François Madore, et al.
Circulation (2023) Vol. 149, Iss. 2, pp. 124-134
Closed Access | Times Cited: 18
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities
Riccardo Sarzani, Matteo Landolfo, Chiara Di Pentima, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 6
Management of Resistant Hypertension—An Update
John M. Giacona, Weerapat Kositanurit, Wanpen Vongpatanasin
JAMA Internal Medicine (2024) Vol. 184, Iss. 4, pp. 433-433
Closed Access | Times Cited: 5
Associating plasma aldosterone concentration with the prevalence of MAFLD in hypertensive patients: insights from a large-scale cross-sectional study
Shen Di, Xintian Cai, Junli Hu, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 5
Efficacy and Safety of Aldosterone Synthase Inhibitors for Hypertension: A Meta-Analysis of Randomized Controlled Trials and Systematic Review
Luigi Marzano, M Merlo, Nicola Martinelli, et al.
Hypertension (2025)
Closed Access
Novel pharmacological approaches to lowering blood pressure and managing hypertension
Matthew Sayer, David J. Webb, Neeraj Dhaun
Nature Reviews Cardiology (2025)
Closed Access
Nationwide, Pragmatic, Direct-to-Patient Primary Aldosteronism Testing Program
Jenifer M. Brown, Laura C Tsai, E Abel, et al.
Hypertension (2025)
Closed Access
Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors
Wryan Helmeczi, Gregory L. Hundemer
Current Opinion in Nephrology & Hypertension (2025)
Closed Access
Evaluation of Aldosterone Suppression by Cinnarizine, a Putative Cav1.3 Inhibitor
Elisabeth Ng, Yun-Ni Lee, Angela E. Taylor, et al.
The Journal of Clinical Endocrinology & Metabolism (2025)
Open Access
Continuous flow-through steady state system for in vitro characterization of CYP11B2 inhibitors – impact on enzyme kinetics of steroidogenesis
Dennis Fröbel, Stefanie Hahner, Britta Heinze, et al.
The Journal of Steroid Biochemistry and Molecular Biology (2025), pp. 106736-106736
Open Access
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Subodh Verma, Avinash Pandey, Arjun Pandey, et al.
AJP Heart and Circulatory Physiology (2023) Vol. 326, Iss. 3, pp. H670-H688
Closed Access | Times Cited: 12
Unveiling Novel Molecules and Therapeutic Targets in Hypertension – A Narrative Review
J Stephen, Surbhi Jain, Dimpy Gupta
European Journal of Pharmacology (2024) Vol. 984, pp. 177053-177053
Closed Access | Times Cited: 4
Efficacy and safety of esaxerenone (CS-3150) in primary hypertension: a meta-analysis
Ran Sun, Yali Li, Lei Lv, et al.
Journal of Human Hypertension (2024) Vol. 38, Iss. 2, pp. 102-109
Open Access | Times Cited: 3
Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors
Jared M. Feldman, William H. Frishman, Wilbert S. Aronow
Cardiology in Review (2024)
Closed Access | Times Cited: 3
Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy
Emma Magavern, Vikas Kapil, Manish Saxena, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2024) Vol. 44, Iss. 4, pp. 784-793
Closed Access | Times Cited: 3
Adverse Effects of Aldosterone: Beyond Blood Pressure
Jenifer M. Brown
Journal of the American Heart Association (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 3
Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension—the Importance of a Mechanistic, Personalized Approach
Giulia Nardoianni, Barbara Pala, Alessandra Scoccia, et al.
High Blood Pressure & Cardiovascular Prevention (2024) Vol. 31, Iss. 2, pp. 99-112
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top